Health Care [ 10/12 ] | Biotechnology [ 39/73 ]
NASDAQ | Common Stock
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases.
The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn's disease.
It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company is headquartered in Carlsbad, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 11, 25 | -0.58 Increased by +82.53% | -0.79 Increased by +26.58% |
| May 12, 25 | -0.47 Increased by +89.76% | -0.81 Increased by +41.98% |
| Mar 25, 25 | -0.69 Increased by +89.30% | -1.99 Increased by +65.27% |
| Nov 7, 24 | -2.32 Decreased by -428.18% | -3.35 Increased by +30.63% |
| Aug 9, 24 | -3.32 Decreased by -526.42% | -2.93 Decreased by -13.31% |
| May 13, 24 | -4.59 Decreased by -750.00% | -4.80 Increased by +4.38% |
| Mar 26, 24 | -6.45 Decreased by -199.69% | -5.17 Decreased by -24.76% |
| Nov 9, 23 | -0.44 Increased by +89.00% | -0.39 Decreased by -12.82% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 0.00 Decreased by N/A% | -2.78 M Increased by +31.76% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -2.23 M Increased by +36.77% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 4.00 K Increased by +101.60% | -3.34 M Decreased by -12.55% | Decreased by -83.60 K% Decreased by -7.13 K% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -3.49 M Increased by +3.03% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -4.08 M Decreased by -20.25% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by -100.00% | -3.53 M Decreased by -50.73% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | -250.00 K Decreased by N/A% | -2.97 M Increased by +20.13% | Increased by +1.19 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -3.60 M Increased by +9.90% | Decreased by N/A% Decreased by N/A% |